Top

Published in:

18-12-2023 | Review

The Role of mTOR in Doxorubicin-Altered Cardiac Metabolism: A Promising Therapeutic Target of Natural Compounds

Authors: Fatemeh Yarmohammadi, Mahvash Hesari, Dareuosh Shackebaei

Published in: Cardiovascular Toxicology | Issue 2/2024

Abstract

Doxorubicin (DOX) is commonly used for the treatment of various types of cancer, however can cause serious side effects, including cardiotoxicity. The mechanisms involved in DOX-induced cardiac damage are complex and not yet fully understood. One mechanism is the disruption of cardiac metabolism, which can impair cardiac function. The mammalian target of rapamycin (mTOR) is a key regulator of cardiac energy metabolism, and dysregulation of mTOR signaling has been implicated in DOX-induced cardiac dysfunction. Natural compounds (NCs) have been shown to improve cardiac function in vivo and in vitro models of DOX-induced cardiotoxicity. This review article explores the protective effects of NCs against DOX-induced cardiac injury, with a focus on their regulation of mTOR signaling pathways. Generally, the modulation of mTOR signaling by NCs represents a promising strategy for decreasing the cardiotoxic effects of DOX.

Yarmohmmadi, F., Rahimi, N., Faghir-Ghanesefat, H., Javadian, N., Abdollahi, A., Pasalar, P., & Dehpour, A. R. (2017). Protective effects of agmatine on doxorubicin-induced chronic cardiotoxicity in rat. European Journal of Pharmacology, 796, 39–44. https://doi.org/10.1016/j.ejphar.2016.12.022CrossRefPubMed

Okpara, E. S., Adedara, I. A., Guo, X., Klos, M. L., Farombi, E. O., & Han, S. (2022). Molecular mechanisms associated with the chemoprotective role of protocatechuic acid and its potential benefits in the amelioration of doxorubicin-induced cardiotoxicity: A review. Toxicology Reports, 9, 1713–1724. https://doi.org/10.1016/j.toxrep.2022.09.001CrossRefPubMedPubMedCentral

Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 139, 111708. https://doi.org/10.1016/j.biopha.2021.111708CrossRef

Oxidative medicine and cellular longevity, 2022, 7176282. https://doi.org/10.1155/2022/7176282.

Journal of molecular and cellular cardiology, 69, 4–16. https://doi.org/10.1016/j.yjmcc.2014.01.007.

Szwed, A., Kim, E., & Jacinto, E. (2021). Regulation and metabolic functions of mTORC1 and mTORC2. Physiological Reviews, 101(3), 1371–1426. https://doi.org/10.1152/physrev.00026.2020CrossRefPubMedPubMedCentral

Jiao, Y., Li, Y., Zhang, J., Zhang, S., Zha, Y., & Wang, J. (2022). RRM2 alleviates doxorubicin-induced cardiotoxicity through the AKT/mTOR signaling pathway. Biomolecules, 12(2), 299. https://doi.org/10.3390/biom12020299CrossRefPubMedPubMedCentral

Molecular medicine reports, 23(4), 1–11. https://doi.org/10.3892/mmr.2021.11938.

Johnson, R., Shabalala, S., Louw, J., Kappo, A. P., & Muller, C. J. F. (2017). Aspalathin reverts Doxorubicin-Induced cardiotoxicity through increased autophagy and decreased expression of p53/mTOR/p62 signaling. Molecules (Basel Switzerland), 22(10), 1589. https://doi.org/10.3390/molecules22101589CrossRefPubMed

10.

Yarmohammadi, F., Rezaee, R., & Karimi, G. (2021). Natural compounds against doxorubicin-induced cardiotoxicity: A review on the involvement of Nrf2/ARE signaling pathway. Phytotherapy Research, 35(3), 1163–1175. https://doi.org/10.1002/ptr.6882CrossRefPubMed

11.

Lv, X., Zhu, Y., Deng, Y., Zhang, S., Zhang, Q., Zhao, B., & Li, G. (2020). Glycyrrhizin improved autophagy flux via HMGB1-dependent Akt/mTOR signaling pathway to prevent doxorubicin-induced cardiotoxicity. Toxicology, 441, 152508. https://doi.org/10.1016/j.tox.2020.152508CrossRefPubMed

12.

Phytomedicine: international journal of phytotherapy and phytopharmacology, 99, 154027. https://doi.org/10.1016/j.phymed.2022.154027.

13.

Manolis, A. S., Manolis, A. A., Manolis, T. A., Apostolaki, N. E., Apostolopoulos, E. J., Melita, H., & Katsiki, N. (2021). Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications. Medicinal Research Reviews, 41(1), 275–313. https://doi.org/10.1002/med.21732CrossRefPubMed

14.

Garcia-Ropero, A., Santos-Gallego, C. G., Zafar, M. U., & Badimon, J. J. (2019). Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opinion on drug Metabolism & Toxicology, 15(4), 275–285. https://doi.org/10.1080/17425255.2019.1588886CrossRef

15.

Scientific Reports, 13(1), 8346. https://doi.org/10.21203/rs.3.rs-614231/v1.

16.

Carvalho, R. A., Sousa, R. P. B., Cadete, V. J. J., Lopaschuk, G. D., Palmeira, C. M. M., Bjork, J. A., & Wallace, K. B. (2010). Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology, 270(2), 92–98. https://doi.org/10.1016/j.tox.2010.01.019CrossRefPubMed

17.

Journal of applied toxicology: JAT, 36(11), 1486–1495. https://doi.org/10.1002/jat.3307.

18.

γ‐mediated metabolic reprogramming in cardiomyocytes. The Journal of pathology, 247(3), 320–332. https://doi.org/10.1002/path.5192.

19.

Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018). Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxidative medicine and cellular longevity, 2018, 7582730. https://doi.org/10.1155/2018/7582730

20.

Nolfi-Donegan, D., Braganza, A., & Shiva, S. (2020). Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biology, 37, 101674. https://doi.org/10.1016/j.redox.2020.101674CrossRefPubMedPubMedCentral

21.

Russo, M., Della Sala, A., Tocchetti, C. G., Porporato, P. E., & Ghigo, A. (2021). Metabolic aspects of anthracycline cardiotoxicity. Current Treatment Options in Oncology, 22(2), 18. https://doi.org/10.1007/s11864-020-00812-1CrossRefPubMedPubMedCentral

22.

Shi, S., Chen, Y., Luo, Z., Nie, G., & Dai, Y. (2023). Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Communication and Signaling: CCS, 21(1), 61. https://doi.org/10.1186/s12964-023-01077-5CrossRefPubMedPubMedCentral

23.

Nature cancer, 1(3), 315–328. https://doi.org/10.1038/s43018-020-0039-1.

24.

Chen, Y., & Zhou, X. (2020). Research progress of mTOR inhibitors. European Journal of Medicinal Chemistry, 208, 112820. https://doi.org/10.1016/j.ejmech.2020.112820CrossRefPubMed

25.

Getz, L. J., Runte, C. S., Rainey, J. K., & Thomas, N. A. (2019). Tyrosine phosphorylation as a widespread regulatory mechanism in prokaryotes. Journal of Bacteriology, 201(19), e00205–e00219. https://doi.org/10.1128/JB.00205-19CrossRefPubMedPubMedCentral

26.

Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2018). New insights into the role of mTOR signaling in the cardiovascular system. Circulation Research, 122, 489–505. https://doi.org/10.1161/CIRCRESAHA.117.311147CrossRefPubMedPubMedCentral

27.

Mao, Z., & Zhang, W. (2018). Role of mTOR in glucose and lipid metabolism. International Journal of Molecular Sciences, 19(7). https://doi.org/10.3390/ijms19072043

28.

Molecular cell, 39(2), 171–183. https://doi.org/10.1016/j.molcel.2010.06.022.

29.

Shi, F., & Collins, S. (2023). Regulation of mTOR signaling: Emerging role of cyclic nucleotide-dependent protein kinases and implications for cardiometabolic disease. International Journal of Molecular Sciences, 24(14). https://doi.org/10.3390/ijms241411497

30.

Kaldirim, M., Lang, A., Pfeiler, S., Fiegenbaum, P., Kelm, M., Bönner, F., & Gerdes, N. (2022). Modulation of mTOR signaling in cardiovascular disease to target acute and chronic inflammation. Frontiers in Cardiovascular Medicine, 9, 907348. https://doi.org/10.3389/fcvm.2022.907348CrossRefPubMedPubMedCentral

31.

Aging Cell, 19(4), e13126. https://doi.org/10.1111/acel.13126.

32.

Science (New York, N.Y.), 366(6464), 468–475. https://doi.org/10.1126/science.aay0166.

33.

Nature, 614(7948), 572–579. https://doi.org/10.1038/s41586-022-05652-7.

34.

Dang, T. T., & Back, S. H. (2021). Translation inhibitors activate autophagy master regulators TFEB and TFE3. International Journal of Molecular Sciences, 22(21), 12083. https://doi.org/10.3390/ijms222112083CrossRefPubMedPubMedCentral

35.

Deleyto-Seldas, N., & Efeyan, A. (2021). The mTOR–autophagy axis and the control of metabolism. Frontiers in Cell and Developmental Biology, 9, 655731. https://doi.org/10.3389/fcell.2021.655731CrossRefPubMedPubMedCentral

36.

Sadria, M., & Layton, A. T. (2021). Interactions among mTORC, AMPK and SIRT: A computational model for cell energy balance and metabolism. Cell Communication and Signaling, 19(1), 1–17. https://doi.org/10.1101/2020.10.07.330308CrossRef

37.

Bazer, F. W., Seo, H., Wu, G., & Johnson, G. A. (2020). Interferon tau: Influences on growth and development of the conceptus. Theriogenology, 150, 75–83. https://doi.org/10.1016/j.theriogenology.2020.01.069CrossRefPubMed

38.

Jacinto, E. (2019). Amplifying mTORC2 signals through AMPK during energetic stress. Science Signaling, 12(585), eaax5855. https://doi.org/10.1126/scisignal.aax5855CrossRefPubMed

39.

Fu, W., & Hall, M. N. (2020). Regulation of mTORC2 signaling. Genes, 11(9), 1045. https://doi.org/10.3390/genes11091045CrossRefPubMedPubMedCentral

40.

Nature Communications, 11(1), 575. https://doi.org/10.1038/s41467-020-14430-w.

41.

Journal of Diabetes Research, 2022. https://doi.org/10.1155/2022/1755563.

42.

Shi, B., Ma, M., Zheng, Y., Pan, Y., & Lin, X. (2019). mTOR and Beclin1: Two key autophagy-related molecules and their roles in myocardial ischemia/reperfusion injury. Journal of Cellular Physiology, 234(8), 12562–12568. https://doi.org/10.1002/jcp.28125CrossRefPubMed

43.

Circulation research, 132(5), e148–e165. https://doi.org/10.1161/CIRCRESAHA.119.316388.

44.

Daneshgar, N., Rabinovitch, P. S., & Dai, D. F. (2021). TOR signaling pathway in cardiac aging and heart failure. Biomolecules, 11(2), 168. https://doi.org/10.3390/biom11020168CrossRefPubMedPubMedCentral

45.

Mohan, U. P., PB, T. P., Iqbal, S. T. A., & Arunachalam, S. (2021). Mechanisms of doxorubicin-mediated reproductive toxicity–a review. Reproductive Toxicology, 102, 80–89. https://doi.org/10.1016/j.reprotox.2021.04.003CrossRefPubMed

46.

Oncotarget, 8(3), 4837–4848. https://doi.org/10.18632/oncotarget.13596.

47.

β-LAPachone ameliorates doxorubicin-induced cardiotoxicity via regulating autophagy and Nrf2 signalling pathways in mice. Basic & clinical pharmacology & toxicology, 126(4), 364–373. https://doi.org/10.1111/bcpt.13340.

48.

Biochemical Pharmacology, 180, 114188. https://doi.org/10.1016/j.bcp.2020.114188.

49.

Yu, W., Qin, X., Zhang, Y., Qiu, P., Wang, L., Zha, W., & Ren, J. (2020). Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/Akt/mTOR-dependent manner. Cardiovascular Diagnosis and Therapy, 10(4), 752. https://doi.org/10.21037/cdt-19-707CrossRefPubMedPubMedCentral

50.

Wang, M., Firrman, J., Liu, L., & Yam, K. (2019). A review on flavonoid apigenin: Dietary intake, ADME, antimicrobial effects, and interactions with human gut microbiota. BioMed Research International, 2019, 7010467. https://doi.org/10.1155/2019/7010467

51.

Thomas, S. D., Jha, N. K., Jha, S. K., Sadek, B., & Ojha, S. (2023). Pharmacological and molecular insight on the cardioprotective role of apigenin. Nutrients, 15(2), 385. https://doi.org/10.3390/nu15020385CrossRefPubMedPubMedCentral

52.

Yu, W., Sun, H., Zha, W., Cui, W., Xu, L., Min, Q., & Wu, J. (2017). Apigenin attenuates adriamycin-induced cardiomyocyte apoptosis via the PI3K/AKT/mTOR pathway. Evidence-based complementary and alternative medicine: eCAM, 2017, 2590676. https://doi.org/10.1155/2017/2590676

53.

Biomolecules, 11(3), 392. https://doi.org/10.3390/biom11030392.

54.

Fu, Y. S., Chen, T. H., Weng, L., Huang, L., Lai, D., & Weng, C. F. (2021). Pharmacological properties and underlying mechanisms of curcumin and prospects in medicinal potential. Biomedicine & Pharmacotherapy, 141, 111888. https://doi.org/10.1016/j.biopha.2021.111888CrossRef

55.

Vafaeipour, Z., Razavi, B. M., & Hosseinzadeh, H. (2022). Effects of turmeric (Curcuma longa) and its constituent (curcumin) on the metabolic syndrome: An updated review. Journal of Integrative Medicine, 20(3), 193–203. https://doi.org/10.1039/D2FO02625BCrossRefPubMed

56.

Yarmohammadi, F., Hayes, A. W., & Karimi, G. (2021). Protective effects of curcumin on chemical and drug-induced cardiotoxicity: A review. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394, 1341–1353. https://doi.org/10.1007/s00210-021-02072-8CrossRefPubMed

57.

Psychopharmacology, 240(5), 1179–1190. https://doi.org/10.1007/s00213-023-06357-z.

58.

Zhang, Q., & Wu, L. (2022). In vitro and in vivo cardioprotective effects of curcumin against doxorubicin-induced cardiotoxicity: A systematic review. Journal of oncology, 2022, 7277562. https://doi.org/10.1155/2022/7277562

59.

Yao, H., Zhou, L., Tang, L., Guan, Y., Chen, S., Zhang, Y., & Han, X. (2017). Protective effects of luteolin-7-O-glucoside against starvation-induced injury through upregulation of autophagy in H9c2 cells. Bioscience Trends, 11(5), 557–564. https://doi.org/10.5582/bst.2017.01111CrossRefPubMed

60.

Zang, Y., Igarashi, K., & Li, Y. (2016). Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-A y mice. Bioscience Biotechnology and Biochemistry, 80(8), 1580–1586. https://doi.org/10.1080/09168451.2015.1116928CrossRefPubMed

61.

Nutrients, 14(6), 1155. https://doi.org/10.3390/nu14061155.

62.

Biomolecules, 10(4), 502. https://doi.org/10.3390/biom10040502.

63.

Cardiovascular toxicology, 16(2), 101–110. https://doi.org/10.1007/s12012-015-9317-z.

64.

Biomedicine & Pharmacotherapy, 158, 114203. https://doi.org/10.1016/j.biopha.2022.114203.

65.

Asokan, S. M., Mariappan, R., Muthusamy, S., & Velmurugan, B. K. (2018). Pharmacological benefits of neferine-A comprehensive review. Life Sciences, 199, 60–70. https://doi.org/10.1016/j.lfs.2018.02.032CrossRef

66.

Guolan, D., Lingli, W., Wenyi, H., Wei, Z., Baowei, C., & Sen, B. (2018). Anti-inflammatory effects of neferine on LPS-induced human endothelium via MAPK, and NF-κβ pathways. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 73(9), 541–544. https://doi.org/10.1691/ph.2018.8443CrossRef

67.

Lohanathan, B. P., Rathinasamy, B., Huang, C. Y., & Viswanadha, V. P. (2022). Neferine attenuates doxorubicin-induced fibrosis and hypertrophy in H9c2 cells. Journal of Biochemical and Molecular Toxicology, 36(7), e23054. https://doi.org/10.1002/jbt.23054CrossRefPubMed

68.

Bharathi Priya, L., Baskaran, R., Huang, C. Y., & Vijaya Padma, V. (2018). Neferine modulates IGF-1R/Nrf2 signaling in doxorubicin treated H9c2 cardiomyoblasts. Journal of Cellular Biochemistry, 119(2), 1441–1452. https://doi.org/10.1002/jcb.26305CrossRefPubMed

69.

Van Hung, P. (2016). Phenolic compounds of cereals and their antioxidant capacity. Critical Reviews in Food Science and Nutrition, 56(1), 25–35. https://doi.org/10.1080/10408398.2012.708909CrossRefPubMed

70.

Ma, D., Wang, C., Feng, J., & Xu, B. (2021). Wheat grain phenolics: A review on composition, bioactivity, and influencing factors. Journal of the Science of Food and Agriculture, 101(15), 6167–6185. https://doi.org/10.1002/jsfa.11428CrossRefPubMed

71.

Sahu, R., Dua, T. K., Das, S., De Feo, V., & Dewanjee, S. (2019). Wheat phenolics suppress doxorubicin-induced cardiotoxicity via inhibition of oxidative stress, MAP kinase activation, NF-κB pathway, PI3K/Akt/mTOR impairment, and cardiac apoptosis. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 125, 503–519. https://doi.org/10.1016/j.fct.2019.01.034CrossRefPubMed

72.

Zhao, J., Zhou, H., An, Y., Shen, K., & Yu, L. (2021). Biological effects of corosolic acid as an anti–inflammatory, anti–metabolic syndrome and anti–neoplasic natural compound. Oncology Letters, 21(2), 1. https://doi.org/10.3892/ol.2020.12345ADSCrossRef

73.

International Journal of Molecular Medicine, 45(5), 1425–1435. https://doi.org/10.3892/ijmm.2020.4531.

74.

Alkholifi, F. K., Devi, S., Yusufoglu, H. S., & Alam, A. (2023). The cardioprotective effect of corosolic acid in the diabetic rats: A possible mechanism of the PPAR-γ pathway. Molecules, 28(3), 929. https://doi.org/10.3390/molecules28030929CrossRefPubMedPubMedCentral

75.

Che, Y., Wang, Z., Yuan, Y., Zhou, H., Wu, H., Wang, S., & Tang, Q. (2022). By restoring autophagic flux and improving mitochondrial function, corosolic acid protects against dox-induced cardiotoxicity. Cell Biology and Toxicology, 38(3), 451–467. https://doi.org/10.1007/s10565-021-09619-8CrossRefPubMed

76.

International Journal of Molecular Sciences, 23(23), 15180. https://doi.org/10.3390/ijms232315180.

77.

Wei, Y., Xu, M., Ren, Y., Lu, G., Xu, Y., Song, Y., & Ji, H. (2016). The cardioprotection of dihydrotanshinone I against myocardial ischemia–reperfusion injury via inhibition of arachidonic acid ω-hydroxylase. Canadian Journal of Physiology and Pharmacology, 94(12), 1267–1275. https://doi.org/10.1139/cjpp-2016-0036CrossRefPubMed

78.

κB inflammatory signaling axis: a novel therapeutic pathway of dihydrotanshinone I in doxorubicin-induced cardiotoxicity. Journal of experimental & clinical cancer research: CR, 39(1), 93. https://doi.org/10.1186/s13046-020-01595-x.

79.

Yarmohammadi, F., Karbasforooshan, H., Hayes, A. W., & Karimi, G. (2021). Inflammation suppression in doxorubicin-induced cardiotoxicity: Natural compounds as therapeutic options. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394(10), 2003–2011. https://doi.org/10.1007/s00210-021-02132-zCrossRefPubMed

80.

Fang, Z., Zhang, M., Liu, J., Zhao, X., Zhang, Y., & Fang, L. (2021). Tanshinone IIA: A review of its anticancer effects. Frontiers in Pharmacology, 11, 611087. https://doi.org/10.3389/fphar.2020.611087CrossRefPubMedPubMedCentral

81.

Guo, R., Li, L., Su, J., Li, S., Duncan, S. E., Liu, Z., & Fan, G. (2020). Pharmacological activity and mechanism of tanshinone IIA in related diseases. Drug Design Development and Therapy, 14, 4735–4748. https://doi.org/10.2147/DDDT.S266911CrossRefPubMedPubMedCentral

82.

Feng, J., Liu, L., Yao, F., Zhou, D., He, Y., & Wang, J. (2021). The protective effect of tanshinone IIa on endothelial cells: A generalist among clinical therapeutics. Expert Review of Clinical Pharmacology, 14(2), 239–248. https://doi.org/10.1080/17512433.2021.1878877CrossRefPubMed

83.

He, Z., Sun, C., Xu, Y., & Cheng, D. (2016). Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 84, 1760–1767. https://doi.org/10.1016/j.biopha.2016.10.110CrossRef

84.

Frontiers in Pharmacology, 14, 1165212. https://doi.org/10.3389/fphar.2023.1165212.

85.

Cancers, 11(7), 910. https://doi.org/10.3390/cancers11070910.

86.

Chaudhary, S. K., Sandasi, M., Makolo, F., van Heerden, F. R., & Viljoen, A. M. (2021). Aspalathin: A rare dietary dihydrochalcone from aspalathus linearis (rooibos tea). Phytochemistry Reviews, 1–32. https://doi.org/10.1007/s11101-021-09741-9

87.

Molecules, 24(9), 1713. https://doi.org/10.3390/molecules24091713.

88.

Li, C., Liu, Y., Zhang, Y., Li, J., & Lai, J. (2022). Astragalus polysaccharide: A review of its immunomodulatory effect. Archives of Pharmacal Research, 45(6), 367–389. https://doi.org/10.1007/s12272-022-01393-3CrossRefPubMed

89.

Zheng, Y., Ren, W., Zhang, L., Zhang, Y., Liu, D., & Liu, Y. (2020). A review of the pharmacological action of Astragalus polysaccharide. Frontiers in Pharmacology, 11, 349. https://doi.org/10.3389/fphar.2020.00349CrossRefPubMedPubMedCentral

90.

Liu, D., Chen, L., Zhao, J., & Cui, K. (2018). Cardioprotection activity and mechanism of astragalus polysaccharide in vivo and in vitro. International Journal of Biological Macromolecules, 111, 947–952. https://doi.org/10.1016/j.ijbiomac.2018.01.048CrossRefPubMed

91.

Zhang, Y., Zhou, Q., Ding, X., Wang, H., & Tan, G. (2021). HILIC-MS-based metabolomics reveal that astragalus polysaccharide alleviates doxorubicin-induced cardiomyopathy by regulating sphingolipid and glycerophospholipid homeostasis. Journal of Pharmaceutical and Biomedical Analysis, 203, 114177. https://doi.org/10.1016/j.jpba.2021.114177CrossRefPubMed

92.

Zhang, H., Caprioli, G., Hussain, H., Le, N. P. K., Farag, M. A., & Xiao, J. (2021). A multifaceted review on dihydromyricetin resources, extraction, bioavailability, biotransformation, bioactivities, and food applications with future perspectives to maximize its value. eFood, 2(4), 164–184. https://doi.org/10.53365/efood.k/143518CrossRef

93.

Frontiers in Pharmacology, 12, 3721. https://doi.org/10.3389/fphar.2021.794563.

94.

Wang, Y., Wang, J., Xiang, H., Ding, P., Wu, T., & Ji, G. (2022). Recent update on application of dihydromyricetin in metabolic related diseases. Biomedicine & Pharmacotherapy, 148, 112771. https://doi.org/10.1016/j.biopha.2022.112771CrossRef

95.

Frontiers in pharmacology, 9, 1204. https://doi.org/10.3389/fphar.2018.01204.

96.

Wang, L., & Ma, Q. (2018). Clinical benefits and pharmacology of scutellarin: A comprehensive review. Pharmacology & Therapeutics, 190, 105–127. https://doi.org/10.1016/j.pharmthera.2018.05.006CrossRef

97.

Huang, H., Geng, Q., Yao, H., Shen, Z., Wu, Z., Miao, X., & Shi, P. (2018). Protective effect of scutellarin on myocardial infarction induced by isoprenaline in rats. Iranian Journal of Basic Medical Sciences, 21(3), 267. https://doi.org/10.22038/ijbms.2018.26110.6415ADSCrossRefPubMedPubMedCentral

98.

Xu, L., Chen, R., Ma, X., Zhu, Y., Sun, G., & Sun, X. (2020). Scutellarin protects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasome activation. Phytomedicine, 68, 153169. https://doi.org/10.1016/j.phymed.2020.153169CrossRefPubMed

99.

Chemistry & biodiversity, 20(1), e202200450. https://doi.org/10.1002/cbdv.202200450.

100.

Toxicology in vitro: an international journal published in association with BIBRA, 82, 105366. https://doi.org/10.1016/j.tiv.2022.105366.

101.

Lu, Y., Feng, Y., Liu, D., Zhang, Z., Gao, K., Zhang, W., & Tang, H. (2018). Thymoquinone attenuates myocardial ischemia/reperfusion injury through activation of SIRT1 signaling. Cellular Physiology and Biochemistry, 47(3), 1193–1206. https://doi.org/10.1159/000490216CrossRefPubMed

102.

Tabassum, S., Rosli, N., Ichwan, S. J. A., & Mishra, P. (2021). Thymoquinone and its pharmacological perspective: A review. Pharmacological Research - Modern Chinese Medicine, 1, 100020. https://doi.org/10.1016/j.prmcm.2021.100020CrossRef

103.

Gur, F. M., & Aktas, I. (2021). The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy. Tissue and Cell, 71, 101582. https://doi.org/10.1016/j.tice.2021.101582CrossRefPubMed

104.

Liu, D., & Zhao, L. (2022). Thymoquinone–induced autophagy mitigates doxorubicin–induced H9c2 cell apoptosis. Experimental and Therapeutic Medicine, 24(5), 694. https://doi.org/10.3892/etm.2022.11630CrossRefPubMedPubMedCentral

105.

Nagar, P. S., Rane, S., & Dwivedi, M. (2022). LC-MS/MS standardization and validation of glycyrrhizin from the roots of taverniera cuneifolia: A potential alternative source of glycyrrhiza glabra. Heliyon, 8(8), e10234. https://doi.org/10.1016/j.heliyon.2022.e10234CrossRefPubMedPubMedCentral

106.

Thakur, V., Alcoreza, N., Delgado, M., Joddar, B., & Chattopadhyay, M. (2021). Cardioprotective effect of glycyrrhizin on myocardial remodeling in diabetic rats. Biomolecules, 11(4), 569. https://doi.org/10.3390/biom11040569CrossRefPubMedPubMedCentral

107.

Translational stroke research, 11, 967–982. https://doi.org/10.1007/s12975-019-00772-1.

108.

Mano, Y., Abe, K., Takahashi, M., Higurashi, T., Kawano, Y., Miyazaki, S., & Maeda-Minami, A. (2023). Optimal administration of glycyrrhizin avoids pharmacokinetic interactions with high-dose methotrexate and exerts a hepatoprotective effect. Anticancer Research, 43(4), 1493–1501. https://doi.org/10.21873/anticanres.16298CrossRefPubMed

109.

Jäger, T., Mokos, A., Prasianakis, N. I., & Leyer, S. (2022). Pore-level multiphase simulations of realistic distillation membranes for water desalination. Membranes, 11(4), 569. https://doi.org/10.3390/biom11040569CrossRef

110.

Naunyn-Schmiedeberg’s Archives of Pharmacology, 393, 979–989. https://doi.org/10.1007/s00210-019-01767-3.

111.

Frontiers in Immunology, 11, 1104. https://doi.org/10.3389/fimmu.2020.01104.

112.

κB and PI3K/Akt/mTOR pathways. Molecular immunology, 94, 7–17. https://doi.org/10.1016/j.molimm.2017.12.008.

113.

Oh, H., Choi, A., Seo, N., Lim, J. S., You, J. S., & Chung, Y. E. (2021). Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on post-contrast acute kidney injury. Scientific Reports, 11(1), 1–12. https://doi.org/10.1038/s41598-021-94928-5CrossRef

114.

Malviya, V., Tawar, M., Burange, P., & Jodh, R. (2022). A brief review on resveratrol, 12(2), 157–162. https://doi.org/10.52711/2231-5659.2022.00027

115.

Dyck, G. J. B., Raj, P., Zieroth, S., Dyck, J. R. B., & Ezekowitz, J. A. (2019). The effects of resveratrol in patients with cardiovascular disease and heart failure: A narrative review. International Journal of Molecular Sciences, 20(4), 904. https://doi.org/10.3390/ijms20040904CrossRefPubMedPubMedCentral

116.

Li, T., Tan, Y., Ouyang, S., He, J., & Liu, L. (2022). Resveratrol protects against myocardial ischemia-reperfusion injury via attenuating ferroptosis. Gene, 808, 145968. https://doi.org/10.1016/j.gene.2021.145968CrossRefPubMed

117.

Gu, J., Fan, Y. Q., Zhang, H. L., Pan, J. A., Yu, J. Y., Zhang, J. F., & Wang, C. Q. (2018). Resveratrol suppresses doxorubicin-induced cardiotoxicity by disrupting E2F1 mediated autophagy inhibition and apoptosis promotion. Biochemical Pharmacology, 150, 202–213. https://doi.org/10.1016/j.bcp.2018.02.025CrossRefPubMed

118.

Gu, J., Hu, W., Song, Z. P., Chen, Y. G., Zhang, D. D., & Wang, C. Q. (2016). Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. International Immunopharmacology, 32, 1–7. https://doi.org/10.1016/j.intimp.2016.01.002CrossRefPubMed

119.

Lei, Y., & Klionsky, D. J. (2023). Transcriptional regulation of autophagy and its implications in human disease. Cell Death & Differentiation, 1–14. https://doi.org/10.1038/s41418-023-01162-9

120.

Rahman, M. A., Cho, Y., Nam, G., & Rhim, H. (2021). Antioxidant compound, oxyresveratrol, inhibits APP production through the AMPK/ULK1/mTOR-mediated autophagy pathway in mouse cortical astrocytes. Antioxidants, 10(3), 408. https://doi.org/10.3390/antiox10030408CrossRefPubMedPubMedCentral

121.

Gomes, C. L., de Albuquerque Wanderley Sales, V., Gomes de Melo, C., Ferreira da Silva, R. M., Nishimura, V., Rolim, R. H., L. A., & Rolim Neto, P. J. (2021). Beta-lapachone: Natural occurrence, physicochemical properties, biological activities, toxicity and synthesis. Phytochemistry, 186, 112713. https://doi.org/10.1016/j.phytochem.2021.112713CrossRefPubMed

122.

β-Lapachone protects against doxorubicin-induced nephrotoxicity via NAD+/AMPK/NF-kB in mice. Naunyn-Schmiedeberg’s Archives of Pharmacology, 392, 633–640. https://doi.org/10.1007/s00210-019-01619-0.

123.

Tabrizi, F. B., Yarmohammadi, F., Hayes, A. W., & Karimi, G. (2022). The modulation of SIRT1 and SIRT3 by natural compounds as a therapeutic target in doxorubicin-induced cardiotoxicity: A review. Journal of Biochemical and Molecular Toxicology, 36(1), e22946. https://doi.org/10.1002/jbt.22946CrossRefPubMed

124.

Chemico-biological interactions, 317, 108972. https://doi.org/10.1016/j.cbi.2020.108972.

125.

Human Gene Therapy, 33(11–12), 598–613. https://doi.org/10.1089/hum.2021.176.

126.

Frontiers in Pharmacology, 13, 870699. https://doi.org/10.3389/fphar.2022.870699.

127.

Liu, D., & Zhao, L. (2022). Spinacetin alleviates doxorubicin-induced cardiotoxicity by initiating protective autophagy through SIRT3/AMPK/mTOR pathways. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 101, 154098. https://doi.org/10.1016/j.phymed.2022.154098CrossRefPubMed

128.

Frontiers in Pharmacology, 9, 824. https://doi.org/10.3389/fphar.2018.00824.

129.

Murcia, M. A., Jiménez-Monreal, A. M., Gonzalez, J., & Martínez-Tomé, M. (2020). Chapter 11 - Spinach. In A. K. B. T.-N. C. and A. P. of F. and V. Jaiswal (Ed.), (pp. 181–195). Academic Press. https://doi.org/10.1016/B978-0-12-812780-3.00011-8

130.

Zhang, T., Liu, J., Tong, Q., & Lin, L. (2020). SIRT3 acts as a positive autophagy regulator to promote lipid mobilization in adipocytes via activating AMPK. International Journal of Molecular Sciences, 21(2), 372. https://doi.org/10.3390/ijms21020372CrossRefPubMedPubMedCentral

Title: The Role of mTOR in Doxorubicin-Altered Cardiac Metabolism: A Promising Therapeutic Target of Natural Compounds
Authors: Fatemeh Yarmohammadi
Mahvash Hesari
Dareuosh Shackebaei
Publication date: 18-12-2023
Publisher: Springer US
Published in: Cardiovascular Toxicology / Issue 2/2024
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-023-09820-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of mTOR in Doxorubicin-Altered Cardiac Metabolism: A Promising Therapeutic Target of Natural Compounds

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment

Effects of Electronic Cigarette Vaping on Cardiac and Vascular Function, and Post-myocardial Infarction Remodeling in Rats

Cardioprotective Effects of Leucine Supplementation against Doxorubicin-Induced Cardiotoxicit

Diabetic Cardiomyopathy and Cell Death: Focus on Metal-Mediated Cell Death

Evaluation of Environmental Contamination by Heavy Metals and Relationship with Cardiovascular Risk in a Population of Barcarena-PA

Blockade of ZFX Alleviates Hypoxia-Induced Pulmonary Vascular Remodeling by Regulating the YAP Signaling